Cancer immunogenicity, danger signals, and DAMPs: What, when, and how?

BioFactors

Volumn 39, Issue 4, 2013, Pages 355-367

  Garg, Abhishek D ^a   Dudek, Aleksandra M ^a   Agostinis, Patrizia ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Anti tumor immunity; ICD inducers; Immunogenic cell death; Tumor immunology; Viral response

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BIGLYCAN; CYCLOPHILIN A; F ACTIN; FIBRINOGEN; FIBRONECTIN; GENOMIC DNA; HEAT SHOCK PROTEIN; HEPARAN SULFATE; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP N1 PROTEIN; HYALURONIC ACID; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 33; INTERLEUKIN 6; MICRORNA; ONCOLYTIC VIRUS; PROTEIN; PROTEIN BCL 2; PURINERGIC P2 RECEPTOR; RECEPTOR; SMALL NUCLEAR RIBONUCLEOPROTEIN; TENASCIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; VERSICAN;

ADAPTIVE IMMUNITY; APOPTOSIS; CANCER IMMUNOLOGY; CANCER RADIOTHERAPY; CANCER THERAPY; CELL DEATH; CELL MATURATION; CELLULAR IMMUNITY; DAMAGE ASSOCIATED MOLECULAR PATTERN; DENDRITIC CELL; ENDOPLASMIC RETICULUM STRESS; EXOSOME; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENIC CELL DEATH; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LIPID PEROXIDATION; NONHUMAN; OXIDATION REDUCTION STATE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANIMAL; CELL COMMUNICATION; IMMUNOLOGY; INNATE IMMUNITY; NEOPLASM; TUMOR ESCAPE;

ANIMALS; APOPTOSIS; CELL COMMUNICATION; ENDOPLASMIC RETICULUM STRESS; HUMANS; IMMUNITY, INNATE; NEOPLASMS; TUMOR ESCAPE;

EID: 84881668150     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1125     Document Type: Review

References (120)

1. Hanahan, D. and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.
2. Zitvogel L., Tesniere A., and Kroemer, G. (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6, 715-727.
3. Garg, A. D., Nowis D., Golab J., Vandenabeele P., Krysko D. V., et al. (2010) Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 1805, 53-71.
4. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., and Schreiber, R. D. (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3, 991-998.
5. Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., et al. (2012) Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12, 860-875.
6. Malchow, S., Leventhal, D. S., Nishi, S., Fischer, B. I., Shen, L., et al. (2013) Aire-dependent thymic development of tumor-associated regulatory T cells. Science 339, 1219-1224.
7. Meije, C. B., Swart, G. W., Lepoole, C., Das, P. K., and Van den Oord, J. J. (2009) Antigenic profiles of individual-matched pairs of primary and melanoma metastases. Hum Pathol 40, 1399-1407.
8. Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., et al. (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101, 890-898.
9. Chung, E. Y., Liu, J., Homma, Y., Zhang, Y., Brendolan, A., et al. (2007) Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1. Immunity 27, 952-964.
10. Kleinclauss, F., Perruche, S., Masson, E., de Carvalho Bittencourt, M., Biichle, S., et al. (2006) Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion. Cell Death Differ 13, 41-52.
11. Koenen, H. J., Smeets, R. L., Vink, P. M., van Rijssen, E., Boots, A. M., et al. (2008) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112, 2340-2352.
12. Pardoll, D. M. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12, 252-264.
13. Garg, A. D., Kaczmarek, A., Krysko, O., Vandenabeele, P., Krysko, D. V., et al. (2012) ER stress-induced inflammation: does it aid or impede disease progression? Trends Mol Med 18, 589-598.
14. Blankenstein, T., Coulie, P. G., Gilboa, E., and Jaffee, E. M. (2012) The determinants of tumour immunogenicity. Nat Rev Cancer 12, 307-313.
15. Scanlan, M. J., Gure, A. O., Jungbluth, A. A., Old, L. J., and Chen, Y. T. (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188, 22-32.
16. Kloor, M., Michel, S., and von Knebel Doeberitz, M. (2010) Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer 127, 1001-1010.
17. Wagner, W. M., Ouyang, Q., and Pawelec, G. (2003) The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes. Cancer Immunol Immunother 52, 89-96.
18. Lampen, M. H. and van Hall, T. (2011) Strategies to counteract MHC-I defects in tumors. Curr Opin Immunol 23, 293-298.
19. Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., et al. (2012) An immunosurveillance mechanism controls cancer cell ploidy. Science 337, 1678-1684.
20. Uyttenhove, C., Pilotte, L., Theate, I., Stroobant, V., Colau, D., et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med 9, 1269-1274.
21. Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., et al. (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197-203.
22. Garg, A. D., Nowis, D., Golab, J., and Agostinis, P. (2010) Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis 15, 1050-1071.
23. Garg, A. D., Krysko, D. V., Vandenabeele, P., and Agostinis, P. (2011) DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown. Photochem Photobiol Sci 10, 670-680.
24. Garg, A. D., Krysko, D. V., Vandenabeele, P., and Agostinis P. (2012) The emergence of phox-ER stress induced immunogenic apoptosis. Oncoimmunology 1, 786-788.
25. Kroemer, G., Galluzzi, L., Kepp, O., and Zitvogel, L. (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51-72.
26. Garg, A. D., Martin, S., Golab, J., and Agostinis, P. (2013) Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ, DOI: 10.1038/cdd.2013.48.
27. Galluzzi, L., Kepp, O., and Kroemer, G. (2012) Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. EMBO J 31, 1055-1057.
28. Dudek, A. M., Garg, A. D., Krysko, D. V., De Ruysscher, D. and Agostinis, P. (2013) Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev, DOI: 10.1016/j.cytogfr.2013.01.005.
29. Bianchi, M. E. (2007) DAMPs, |PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81, 1-5.
30. Seong, S. Y. and Matzinger, P. (2004) Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 4, 469-478.
31. Matzinger, P. (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991-1045.
32. Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13, 54-61.
33. Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., et al. (2012) A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 31, 1062-1079.
34. Korbelik, M., Sun, J., and Cecic, I. (2005) Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res 65, 1018-1026.
35. Garg, A. D., Nowis, D., Golab, J., and Agostinis, P. (2010) Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis 15, 1050-1071.
36. Suzuki, S. and Kulkarni, A. B. (2010) Extracellular heat shock protein HSP90beta secreted by MG63 osteosarcoma cells inhibits activation of latent TGF-beta1. Biochem Biophys Res Commun 398, 525-531.
37. Zitvogel, L., Kepp, O., and Kroemer, G. (2010) Decoding cell death signals in inflammation and immunity. Cell 140, 798-804.
38. Iwata, A., Morgan-Stevenson, V., Schwartz, B., Liu, L., Tupper, J., et al. (2010) Extracellular BCL2 proteins are danger-associated molecular patterns that reduce tissue damage in murine models of ischemia-reperfusion injury. PLoS One 5, e9103.
39. Iyer, S. S., Pulskens, W. P., Sadler, J. J., Butter, L. M., Teske, G. J., et al. (2009) Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci USA 106, 20388-20393.
40. Manfredi, A. A. and Rovere-Querini, P. (2010) The mitochondrion--a Trojan horse that kicks off inflammation? N Engl J Med 362, 2132-2134.
41. Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., et al. (2010) Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464, 104-107.
42. Babelova, A., Moreth, K., Tsalastra-Greul, W., Zeng-Brouwers, J., Eickelberg, O., et al. (2009) Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem 284, 24035-24048.
43. Schaefer, L. (2010) Extracellular matrix molecules: endogenous danger signals as new drug targets in kidney diseases. Curr Opin Pharmacol 10, 185-190.
44. Goh, F. G., Piccinini, A. M., Krausgruber, T., Udalova, I. A., and Midwood, K. S. (2010) Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J Immunol 184, 2655-2662.
45. Ichim, T. E., Zhong, Z., Kaushal, S., Zheng, X., Ren, X., et al. (2008) Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med 6, 37.
46. Rubartelli, A. and Lotze, M. T. (2007) Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 28, 429-436.
47. Krysko, D. V., Agostinis, P., Krysko, O., Garg, A. D., Bachert, C., et al. (2011) Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 32, 157-164.
48. Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., et al. (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202, 1691-1701.
49. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., et al. (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13, 1050-1059.
50. Gardai, S. J., McPhillips, K. A., Frasch, S. C., Janssen, W. J., Starefeldt, A., et al. (2005) Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123, 321-334.
51. Garg, A. D., Krysko, D. V., Vandenabeele, P., and Agostinis, P. (2012) Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother 61, 215-221.
52. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., et al. (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15, 1170-1178.
53. Lotze, M. T., Zeh, H. J., Rubartelli, A., Sparvero, L. J., Amoscato, A. A., et al. (2007) The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 220, 60-81.
54. Tosch, C., Geist, M., Ledoux, C., Ziller-Remi, C., Paul, S., et al. (2009) Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy. Cancer Gene Ther 16, 310-319.
55. Liu, Y., Chen, G. Y., and Zheng, P. (2009) CD24-Siglec G/10 discriminates danger-from pathogen-associated molecular patterns. Trends Immunol 30, 557-561.
56. Chen, G. Y., Tang, J., Zheng, P., and Liu, Y. (2009) CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323, 1722-1725.
57. Fridman, W. H., Pages, F., Sautes-Fridman, C., and Galon, J. (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12, 298-306.
58. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10, 942-949.
59. Gao, Q., Qiu, S. J., Fan, J., Zhou, J., Wang, X. Y., et al. (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25, 2586-2593.
60. Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., et al. (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69, 2000-2009.
61. Schreck, S., Friebel, D., Buettner, M., Distel, L., Grabenbauer, G., et al. (2009) Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 27, 31-39.
62. Yoon, N. K., Maresh, E. L., Shen, D., Elshimali, Y., Apple, S., et al. (2010) Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol 41, 1794-1801.
63. Carreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A., et al. (2006) High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108, 2957-2964.
64. Tzankov, A., Meier, C., Hirschmann, P., Went, P., Pileri, S. A., et al. (2008) Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 93, 193-200.
65. Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., et al. (2009) Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27, 186-192.
66. Frey, D. M., Droeser, R. A., Viehl, C. T., Zlobec, I., Lugli, A., et al. (2010) High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 126, 2635-2643.
67. Mocellin, S., Marincola, F. M., and Young, H. A. (2005) Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78, 1043-1051.
68. Szczepanski, M., Stelmachowska, M., Stryczynski, L., Golusinski, W., Samara, H., et al. (2007) Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur Arch Otorhinolaryngol 264, 525-530.
69. Sato, Y., Goto, Y., Narita, N., and Hoon, D. S. (2009) Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron 2, 205-214.
70. Demaria, S., Pikarsky, E., Karin, M., Coussens, L. M., Chen, Y. C., et al. (2010) Cancer and inflammation: promise for biologic therapy. J Immunother 33, 335-351.
71. Gamrekelashvili, J., Ormandy, L. A., Heimesaat, M. M., Kirschning, C. J., Manns, M. P., et al. (2012) Primary sterile necrotic cells fail to cross-prime CD8(+) T cells. Oncoimmunology 1, 1017-1026.
72. Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A. C., et al. (2009) Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28, 578-590.
73. Rutkowski, D. T. and Kaufman, R. J. (2004) A trip to the ER: coping with stress. Trends Cell Biol 14, 20-28.
74. Verfaillie, T., Garg, A. D., and Agostinis, P. (2010) Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Lett 332:249-264.
75. Ron, D. and Walter, P. (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8, 519-529.
76. Tabas, I. and Ron, D. (2011) Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 13, 184-190.
77. Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., et al. (2000) Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287, 664-666.
78. Tardif, K. D., Mori, K., Kaufman, R. J., and Siddiqui, A. (2004) Hepatitis C virus suppresses the IRE1-XBP1 pathway of the unfolded protein response. J Biol Chem 279, 17158-17164.
79. Mekahli, D., Bultynck, G., Parys, J. B., De Smedt, H., and Missiaen, L. (2011) Endoplasmic-reticulum calcium depletion and disease. Cold Spring Harbor Perspect Biol 3:a004317.
80. Verfaillie, T., Rubio, N., Garg, A. D., Bultynck, G., Rizzuto, R., et al. (2012) PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ 19, 1880-1891.
81. Garg, A. D., Hippargi, R., and Gandhare, A. (2008) Toad skin-secretions: Potent source of pharmacologically and therapeutically significant compounds. Int J Pharmacology, 5, DOI: 10.5580/18b6.
82. Tsai, C. F., Yeh, W. L., Huang, S. M., Tan, T. W., and Lu, D. Y. (2012) Wogonin induces reactive oxygen species production and cell apoptosis in human glioma cancer cells. Int J Mol Sci 13, 9877-9892.
83. Yang, Y., Li, X. J., Chen, Z., Zhu, X. X., Wang, J., et al. (2012) Wogonin induced calreticulin/annexin A1 exposure dictates the immunogenicity of cancer cells in a PERK/AKT dependent manner. PLoS One 7, e50811.
84. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L. (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56, 185-229.
85. Vergely, C., Delemasure, S., Cottin, Y., and Rochette, L. (2007) Preventing the cardiotoxic effects of anthracyclines: from basic concepts to clinical data. Heart Metab 35, 1-7.
86. Garg, A. D., Bose, M., Ahmed, M. I., Bonass, W. A., and Wood, S. R. (2012) In vitro studies on erythrosine-based photodynamic therapy of malignant and pre-malignant oral epithelial cells. PLoS One 7, e34475.
87. Matzinger, P. (2002) The danger model: a renewed sense of self. Science 296, 301-305.
88. Zhao, Y., Sui, X., and Ren, H. (2010) From procaspase-8 to caspase-8: revisiting structural functions of caspase-8. J Cell Physiol 225, 316-320.
89. Reubold, T. F. and Eschenburg, S. (2012) A molecular view on signal transduction by the apoptosome. Cell Signal 24, 1420-1425.
90. Bratton, D. L., Fadok, V. A., Richter, D. A., Kailey, J. M., Guthrie, L. A., et al. (1997) Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J Biol Chem 272, 26159-26165.
91. Wlodkowic, D., Telford, W., Skommer, J., and Darzynkiewicz, Z. (2011) Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol 103, 55-98.
92. Tesniere, A., Schlemmer, F., Boige, V., Kepp, O., Martins, I., et al (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482-491.
93. Obeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., et al. (2007) Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 14, 1848-1850.
94. Brusa, D., Garetto, S., Chiorino, G., Scatolini, M., Migliore, E., et al. (2008) Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. Vaccine 26, 6422-6432.
95. Suzuki, Y., Mimura, K., Yoshimoto, Y., Watanabe, M., Ohkubo, Y., et al. (2012) Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 72, 3967-3976.
96. Garrido, G., Rabasa, A., Sanchez, B., Lopez, M. V., Blanco, R., et al. (2011) Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol 187, 4954-4966.
97. Miyamoto, S., Inoue, H., Nakamura, T., Yamada, M., Sakamoto, C., et al. (2012) Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res 72, 2609-2621.
98. Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., et al. (2009) Chemotherapy induces ATP release from tumor cells. Cell Cycle 8, 3723-3728.
99. Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., et al (2011) Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573-1577.
100. Stangl, S., Themelis, G., Friedrich, L., Ntziachristos, V., Sarantopoulos, A., et al. (2011) Detection of irradiation-induced, membrane heat shock protein 70 (Hsp70) in mouse tumors using Hsp70 Fab fragment. Radiother Oncol 99, 313-316.
101. Chen, H. M. Wang, P. H., Chen, S. S., Wen, C. C., Chen, Y. H., et al. (2012) Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine. Cancer Immunol Immunother 61:1989-2002.
102. Spisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., et al. (2007) Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 109, 4839-4845.
103. Garg, A. D., Verfaillie, T., Rubio, N., Ferreira, G. B., Mathieu, C., et al. (2010) Hypericin-PDT treatment of cancer cells leads to surface exposure/extracellular release of DAMPs and activates human immature dendritic cells. Belgian J Med Oncol 4, 93-94.
104. Panaretakis, T., Joza, N., Modjtahedi, N., Tesniere, A., Vitale, I., et al. (2008) The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 15, 1499-1509.
105. Maes, H., Rubio, N., Garg, A. D., and Agostinis, P. (2013) Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med, DOI: 10.1016/j.molmed.2013.04.005.
106. Chekeni, F. B., Elliott, M. R., Sandilos, J. K., Walk, S. F., Kinchen, J. M., et al. (2010) Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature 467, 863-867.
107. Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., et al. (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282-286.
108. Garg, A. D., Dudek, A. M., Ferreira, G. B., Verfaillie, T., Vandenabeele, P., et al. (2013) ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy (In Press).
109. Fulda, S. (2009) Caspase-8 in cancer biology and therapy. Cancer Lett 281, 128-133.
110. Rampino, N., Yamamoto, H., Ionov, Y., Li, Y., Sawai, H., et al. (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275, 967-969.
111. Yamamoto, H., Sawai, H., and Perucho, M. (1997) Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 57, 4420-4426.
112. Meijerink, J. P., Mensink, E. J., Wang, K., Sedlak, T. W., Sloetjes, A. W., et al. (1998) Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 91, 2991-2997.
113. Garg, A. D., Krysko, D. V., Vandenabeele, P., and Agostinis, P. (2012) The emergence of phox-ER stress induced immunogenic apoptosis. Oncoimmunology 1, 787-789.
114. Levy, D. E., Marie, I. J., and Durbin, J. E. (2011) Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol 1, 476-486.
115. Rathinam, V. A. and Fitzgerald, K. A. (2011) Cytosolic surveillance and antiviral immunity. Curr Opin Virol 1, 455-462.
116. Zitvogel, L., Kroemer, G., Delahaye, N., Ma, Y., Kepp, O. (2013) U.S. Patent Trademark Office (U. S. P. T. Office, ed), Institut Gustave Roussy (Villejuif, France). Available at: http://www.freepatentsonline.com/y2013/0052160.html).
117. Buytaert, E., Matroule, J. Y., Durinck, S., Close, P., Kocanova, S., et al. (2008) Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells. Oncogene 27, 1916-1929.
118. Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., et al. (2011) Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 17, 1094-1100.
119. Yang, Y., Liu, C., Peng, W., Lizee, G., Overwijk, W. W., et al. (2012) Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 120, 4533-4543.
120. Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., et al. (2013) Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 123, 1371-1381.